Extended Therapy With Letrozole and Ovarian Suppression in Premenopausal Patients With Breast Cancer After Tamoxifen

Micro-Abstract A single-arm phase II study (goal, n = 50) evaluated the feasibility of administering 2 years of ovarian suppression with letrozole to patients with breast cancer who remained premenopausal after adjuvant tamoxifen. This study closed owing to poor accrual (actual patients treated, n =...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical breast cancer 2014-12, Vol.14 (6), p.413-416
Hauptverfasser:	Ruddy, Kathryn J, DeSantis, Stephen D, Barry, William, Guo, Hao, Block, Caroline C, Borges, Virginia, Winer, Eric P, Partridge, Ann H
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Hormonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Aromatase Inhibitors - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Chemotherapy, Adjuvant Dyspareunia Endocrine therapy Feasibility Studies Female Follow-Up Studies Gonadotropin-Releasing Hormone Hematology, Oncology and Palliative Medicine Hot flashes Humans Middle Aged Neoplasm Grading Neoplasm Staging Nitriles - therapeutic use Obstetrics and Gynecology Ovariectomy Pain Premenopause Prognosis Survival Rate Tamoxifen - therapeutic use Toxicity Triazoles - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract A single-arm phase II study (goal, n = 50) evaluated the feasibility of administering 2 years of ovarian suppression with letrozole to patients with breast cancer who remained premenopausal after adjuvant tamoxifen. This study closed owing to poor accrual (actual patients treated, n = 16) over 3.5 years, and a quarter of enrollees stopped treatment owing to toxicity. Future studies of this approach may be challenging.
ISSN:	1526-8209 1938-0666
DOI:	10.1016/j.clbc.2014.04.007